Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM32 immunotherapy versus placebo for grass pollen allergy: nasal immunoglobulin study
2012-004194-12Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Oct 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in grass pollen allergy and seasonal allergic rhinitis (SAR) comparing BM32 with Placebo (2 arms). Primary endpoint: Change in allergen-specific immunoglobulin levels in nasal secretions. Started Oct 2012; status: completed.
02
Drugs
BM32
03
Conditions
grass pollen allergyseasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2012-004194-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004194-12.